Skip to search formSkip to main contentSkip to account menu

Zevalin

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ibritumomab tiuxetanyttrium-90-ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)
PurposeThe aim of this study was to carry out two different dose estimation approaches in patients with non-Hodgkin’s lymphoma… 
2008
2008
Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG…
The 5-year survival rate of patients with limited disease (LD) and aggressive histologies of non-Hodgkin lymphoma (NHL) who have… 
Review
2005
Review
2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
AIM Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B… 
2005
2005
Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.
Introduction: Elderly patients (pts) with high risk DLBCL represent an increasing demographic, are often underserved in clinical… 
2004
2004
Experimental determination of calibration settings for plastic syringes containing solutions of 90Y using commercial radionuclide calibrators.
Review
2004
Review
2004
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation… 
Review
2004
Review
2004
Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-Hodgkin's lymphoma. Several monoclonal… 
Review
2004
Review
2004
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Radioimmunotherapy is a recently approved treatment modality for non-Hodgkin's lymphoma that enables physicians to target… 
2004
2004
90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.
Twenty-eight patients with relapsed or refractory CD20+ NHL have been enrolled in an ongoing phase I trial of dose-escalated 90YZ… 
2003
2003
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
Zevalin (ibritumomab tiuxetan) radioimmunotherapy is a novel treatment for non-Hodgkin's lymphoma (NHL). The Zevalin regimen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)